China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use authorization (EUA) for its inhalable recombinant novel coronavirus vaccine (adenovirus type 5 vector) in Indonesia. This marks a significant milestone in the global fight against COVID-19, as the company expands its vaccine’s availability to another key market.
Convidecia: Background and Approvals
Convidecia, the recombinant novel coronavirus vaccine (adenovirus type 5 vector), was co-developed by the China Academy of Military Medical Sciences. It obtained military special need drug approval in June 2020. Additionally, the inhalable recombinant new coronavirus vaccine (type 5 adenovirus vector), also co-developed with the Academy of Military Medical Sciences, received clinical trial approval in China in March 2021. The vaccine became the first of its kind globally after gaining conditional approval from the National Medical Products Administration (NMPA) in September 2022. Previously, Morocco issued an EUA for the vaccine in November of last year.
Global Impact and Market Expansion
The EUA in Indonesia further solidifies CanSino Biologics’ position as a leading player in the development and distribution of COVID-19 vaccines. The inhalable form of the vaccine offers a convenient and non-invasive alternative to traditional injection methods, potentially increasing vaccination rates and accessibility. This approval in Indonesia is expected to contribute to the global efforts to combat the pandemic, providing another effective tool in the arsenal against COVID-19.-Fineline Info & Tech
